BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said its leadership will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said its leadership will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 5:15 p.m. PT. A live webcast will be available on the company’s Events page and a replay will remain accessible for at least 90 days after the presentation.
This provides investors a scheduled opportunity for management commentary on clinical programs and strategy.
Details
News Market Reaction – BBOT
On Dec 17, the first trading day after this news, BBOT closed 3.54% below the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 12, 2026
- Scheduled conference presentation date
- Presentation time
- 5:15 p.m. PT
- Scheduled JPM Healthcare Conference time slot
- Webcast replay window
- 90 days
- Replay of conference webcast available for at least 90 days
Historical Context
-
Inducement stock options granted under 2025 plan at market exercise price.
-
Late-breaking preclinical data for BBO-10203 showing anti-tumor activity.
-
Planned presentations at two December healthcare investor conferences.
-
Q3 2025 results and pipeline update with cash runway into 2028.
-
Announcement of participation in Jefferies Global Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT.
A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. A replay of the webcast will be available for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.